Organon (NYSE: OGN) insider transactions
In the twelve months to 10 November 2026, executives and directors of Organon reported 1 open-market sale of 14,761 shares ($200,307) and 2 open-market purchases of 91,848 shares ($854,704), by 3 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 7 November 2026 | Holzbaur Lynette | SVP and Corporate Controller | Option exercise | +2,418 | — | 4,590 | Form 4 |
| 7 November 2026 | Holzbaur Lynette | SVP and Corporate Controller | Shares withheld for tax | −689 | $13.87 | 3,901 | Form 4 |
| 7 November 2026 | Arjona Ferreira Juan Camilo | Head of R&D & CMO | Option exercise | +6,447 | — | 43,879 | Form 4 |
| 7 November 2026 | Arjona Ferreira Juan Camilo | Head of R&D & CMO | Shares withheld for tax | −2,314 | $13.87 | 41,565 | Form 4 |
| 7 November 2026 | Drinane Juliana Papa | Head of Mfg & Supply | Option exercise | +3,626 | — | 22,101 | Form 4 |
| 7 November 2026 | Drinane Juliana Papa | Head of Mfg & Supply | Shares withheld for tax | −1,242 | $13.87 | 20,859 | Form 4 |
| 5 November 2026 | Holzbaur Lynette | SVP and Corporate Controller | Option exercise | +3,038 | — | 3,038 | Form 4 |
| 5 November 2026 | Holzbaur Lynette | SVP and Corporate Controller | Shares withheld for tax | −866 | $13.83 | 2,172 | Form 4 |
| 11 August 2026 | Arjona Ferreira Juan Camilo | Head of R&D & CMO | Option exercise | +11,519 | — | 41,566 | Form 4 |
| 11 August 2026 | Arjona Ferreira Juan Camilo | Head of R&D & CMO | Shares withheld for tax | −4,134 | $13.62 | 37,432 | Form 4 |
| 5 August 2026 | Drinane Juliana Papa | Head of Mfg & Supply | Open-market sale | −14,761 | $13.57 | 18,475 | Form 4 |
| 6 May 2026 | Holzbaur Lynette | SVP and Corporate Controller | Open-market purchase | +26,448 | $13.35 | 52,851 | Form 4 |
| 31 March 2026 | Morrissey Joseph T. Jr. | Interim CEO | Option exercise | +7,795 | — | 113,339 | Form 4 |
| 31 March 2026 | Morrissey Joseph T. Jr. | Interim CEO | Shares withheld for tax | −2,221 | $5.70 | 111,118 | Form 4 |
| 31 March 2026 | Morrissey Joseph T. Jr. | Interim CEO | Option exercise | +16,789 | — | 127,907 | Form 4 |
| 31 March 2026 | Morrissey Joseph T. Jr. | Interim CEO | Shares withheld for tax | −4,784 | $5.70 | 123,123 | Form 4 |
| 31 March 2026 | Holzbaur Lynette | SVP and Corporate Controller | Option exercise | +4,252 | — | 22,813 | Form 4 |
| 31 March 2026 | Holzbaur Lynette | SVP and Corporate Controller | Shares withheld for tax | −1,212 | $5.70 | 21,601 | Form 4 |
| 31 March 2026 | Holzbaur Lynette | SVP and Corporate Controller | Option exercise | +6,715 | — | 28,316 | Form 4 |
| 31 March 2026 | Holzbaur Lynette | SVP and Corporate Controller | Shares withheld for tax | −1,914 | $5.70 | 26,402 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Organon page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.